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Dual Antiplatelet Therapy with Ticagrelor vs Clopidogrel in Patients with
Acute Coronary Syndrome
Abstract
Background: Dual antiplatelet therapy (DAPT) is an effective secondary prevention and an
essential component of treatment after patients suffering from acute coronary syndrome (ACS).
Recently, clinicians rapidly switched to DAPT with ticagrelor as the preferred treatment option
after it was introduced in 2011. Compared to clopidogrel, ticagrelor is not a prodrug and does not
require metabolic activation to inhibit the platelet P2Y12 receptor. It is the first reversible oral
P2Y12 receptor antagonist; and its effect on platelet inhibition is more pronounced compared to
clopidogrel.
Purpose: The purpose of this comprehensive review was to evaluate the efficacy and safety data
of ticagrelor when compared with clopidogrel in ACS patients.
Methods: A comprehensive literature review was conducted using Tripdatabases and Pubmed
search engines was searched through June 2022 using the terms: “dual antiplatelet therapy,”
“antiplatelet monotherapy,” “ticagrelor vs clopidogrel,” “reduce recurrent atherothrombotic
events,” “cardiovascular adverse events,” “coronary heart disease,” “acute coronary syndrome,”
“myocardial infarction.” Inclusion criteria were recently published studies (at least 15 studies
within the last five years from the day this review was performed) comparing the efficacy of
ticagrelor with clopidogrel or placebo. The type of trials could be retrospective studies or
prospective randomized controlled studies with complete data and reportable clinical outcomes.
Exclusion criteria were case reports, repeated publications, animal experiments, and studies that
were poorly designed with errors, incomplete data, or without clinical outcomes.
Conclusions: Through the literature review from many blinded, randomized controlled trials and
studies, ticagrelor has successfully shown its superior efficacy in reducing the rate of
cardiovascular adverse events in ACS patients and shown no significant difference in the rate of
major bleeding between ticagrelor and clopidogrel.
Key Words: Dual antiplatelet therapy, antiplatelet monotherapy, ticagrelor, ticagrelor vs
clopidogrel, recurrent thrombotic events, cardiovascular adverse events, acute coronary
syndrome, coronary heart disease, myocardial infarction, fibrinolysis.
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Dual Antiplatelet Therapy with Ticagrelor vs Clopidogrel in Patients with
Acute Coronary Syndrome

Introduction
Cardiovascular disease affects millions of people annually and is a leading cause of death
and disability.1 According to the global burden of Cardiovascular Diseases and Risk Factors, the
incidence of coronary heart disease and deaths caused by it were increasing significantly, from
12.1 million in 1990, reaching 18.6 million in 2019.2 After acute coronary syndrome (ACS),
especially after acute myocardial infarction (AMI), patients are at high risk for further vascular
events, such as ischemic stroke which is a known complication with devastating consequences.
The incidence of ischemic stroke is between 1.1–4.1% during the first year after myocardial
infarction (MI); and it is potentially associated with an increase in morbidity and mortality.1
Indeed, a study showed an increase of 16% to 19% in absolute mortality rate during the first year
in patients with AMI complicated by ischemic stroke. 3 Moreover, previous ischemic stroke is
also a major predictor of recurrent ischemic stroke after AMI. In real life, these patients are
routinely encountered in clinical practice and constitute a high-risk population with worse
prognosis than the general AMI-population. 1 To help reduce the risk of vascular complications
after ACS, effective secondary prevention is vital, especially to ACS patients with prior stroke.
Currently, dual antiplatelet therapy (DAPT) is an effective secondary prevention and an
essential component of treatment after patients suffering from ACS. 1 A standard treatment in
patients with ACS with or without ST-segment elevation and after stent procedures is DAPT
involving the combination of aspirin and clopidogrel.4 Until 2011, the standard DAPT in Sweden
was still the combination of clopidogrel and aspirin.1,3 However, this standard DAPT did not give
an adequate platelet inhibition response in approximately 15% to 48% of patients.4
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Consequently, this could contribute to a residual high risk of recurrent thrombotic events in these
patients. Therefore, clinicians rapidly switched to ticagrelor, a P2Y12-inhibitor, as the preferred
treatment option after it was introduced in 2011.1 Clopidogrel is a prodrug which needs liver
metabolism to be activated; and its active metabolite irreversibly binds the platelet P2Y12
receptor. Additionally, the onset of clopidogrel is slow. It needs about 2-4 hours to achieve
steady-state platelet inhibition after a loading dose of 600 mg.4 Moreover, this pathway may lead
to unexpected variations in drug activity since it is susceptible to genetic polymorphism.5
Compared to clopidogrel, ticagrelor is not a prodrug and does not require metabolic activation to
inhibit the platelet P2Y12 receptor. It is the first reversible oral P2Y12 receptor antagonist; and
its effect on platelet inhibition is more pronounced.1,4,5 Since it is an active drug with more rapid
onset (within 1.5-3 hours) and offset of action (within 2 hours), the inhibition and recovery of
platelet function with ticagrelor is faster than clopidogrel.5
Because of the advantageous features of ticagrelor, many trials have been conducted to
compare the clinical efficacy and safety data between the use of ticagrelor compared to
clopidogrel in reducing the rate of death from vascular causes, MI or stroke in patients surviving
from ACS. Therefore, the purpose of this review is to evaluate whether the use of DAPT with
ticagrelor would result in a lower risk of recurrent thrombotic events in patients after
experiencing ACS.

Methods
A comprehensive literature review was conducted using Tripdatabases and Pubmed
search engines was searched through June 2022 using the terms: “dual antiplatelet therapy,”
“antiplatelet monotherapy,” “ticagrelor vs clopidogrel,” “reduce recurrent atherothrombotic
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events,” “cardiovascular adverse events,” “coronary heart disease,” “acute coronary syndrome,”
“myocardial infarction.”
Inclusion criteria were recently published studies (at least 15 studies within the last five
years from the day this review was performed) comparing the efficacy of ticagrelor with
clopidogrel or placebo. The type of trials could be retrospective studies or prospective
randomized controlled studies with complete data and reportable clinical outcomes. Exclusion
criteria were case reports, repeated publications, animal experiments, and studies that were
poorly designed with errors, incomplete data, or without clinical outcomes.
In this comprehensive literature review, 20 studies were selected with 16 studies
published within the last five years. Participants were ACS patients who were at least 18 years
with or without ST-elevation in addition to one or more cardiovascular risk factors (for example:
age ≥60 years, diabetes mellitus, chronic renal dysfunction, peripheral arterial disease, transient
ischemic attack, prior myocardial infarction, or ischemic stroke).
The main outcomes were the rates of cardiovascular mortality, MI, stroke, or other
atherothrombotic events and the major bleeding were evaluated in most of the selected studies.

Review of the Literature
One of the biggest trials that were designed to test the efficacy and safety of ticagrelor
compared with clopidogrel in reduction of recurrent thrombotic events in patients with ACS was
the PLATelet inhibition and patient Outcomes (PLATO) trial. PLATO was a multicenter,
double-blinded, and randomized controlled trial in which researchers compared ticagrelor and
clopidogrel for the prevention of adverse cardiovascular events and the bleeding risk.4 The trial
enrolled 18,624 ACS patients with or without ST-segment elevation admitted to the hospital
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from approximately 800 sites in 43 countries.4,6 In this trial, patients were at least 18 years old
with ACS that happened within 24 hours before randomization. In addition, ACS patients
without ST-elevation needed two or more of the following criteria to be enrolled, such as an
electrocardiography showing ischemia, a positive test of cardiac biomarkers, or one of cardiac
risk factors (for example: age ≥60 years, diabetes mellitus, chronic renal dysfunction, peripheral
arterial disease, transient ischemic attack, prior myocardial infarction or ischemic stroke). For
ACS patients with ST-elevation, they needed two more criteria to be enrolled, such as intention
to perform primary percutaneous coronary intervention (PCI), or persistent ST-elevation (at least
0.1 mV in ≥ 2 contiguous leads) or a new left bundle-branch block. Patients who were
contraindicated against the use of clopidogrel, had fibrinolytic therapy within 24 hours, or were
at increased risk of bradycardia were excluded from this trial.4,6 Within 24 hours from the onset
of ACS, eligible patients were randomized in a 1:1 ratio to oral maintenance treatment with
ticagrelor 90 mg twice daily (180-mg loading dose) and clopidogrel 75 mg once daily
(300-to-600-mg loading dose) on a background of aspirin from 6 to 12 months with an estimated
average follow-up of 11 months. The primary efficacy endpoint was the occurrence of death
from vascular causes, MI, or stroke; and the primary safety variable was PLATO-defined major
bleeding.4,6 This trial showed a composite of death from vascular causes, stroke, or MI at 12
months had occurred in 9.8% of patients receiving ticagrelor and 11.7% of those receiving
clopidogrel (P<0.001). There was no significant difference in the rates of major bleeding
between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43).
However, a higher rate of major bleeding not related to coronary-artery bypass grafting (such as
intracranial bleeding) was seen in ticagrelor group compared to clopidogrel group (4.5% vs.
3.8%, P=0.03).6
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The findings from the PLATO trial were supported by the Platelet Reactivity in Acute
Stroke or Transient Ischemic Attack (PRINCE) trial. The PRINCE trial compared the efficacy of
ticagrelor plus aspirin with clopidogrel plus aspirin at 90 days in patients with minor stroke or
with a moderate to high-risk transient ischemic attack. This trial was a prospective study
conducted at 26 centers in China from 08/2015 to 03/2017. There were 675 patients enrolled in
this trial. Key exclusion of this trial was diagnosis of intracranial hemorrhage, any pathology that
could cause neurological symptoms, or contraindication against ticagrelor, clopidogrel, or
aspirin.7 Similar to the PLATO trial, 336 patients were randomly assigned to the
ticagrelor/aspirin group (180 mg loading dose, 90 mg twice daily thereafter) and 339 patients
were assigned to the clopidogrel/aspirin group (300 mg loading dose, 75 mg daily thereafter) on
a background of aspirin within 24 hours of symptom onset. The outcomes of this trial were the
proportion of patients with high platelet reactivity and any stroke recurrence at 90 days.7 As a
result, high platelet reactivity occurred more in the clopidogrel/aspirin group vs the
ticagrelor/aspirin group at the 90th day of the treatment (29.7% vs 12.5%, respectively). This
meant there would be a higher chance of recurrent thrombotic events in patients treated with
clopidogrel/aspirin. Indeed, stroke occurred more in the clopidogrel/aspirin group vs the
ticagrelor/aspirin group (8.8% vs 6.3%, respectively; P=0.20). However, there was no significant
difference seen in the rates of major or minor hemorrhagic events between the ticagrelor/aspirin
and clopidogrel/aspirin groups (4.8% v 3.5%; P=0.42).7 These results were consistent with
findings from the PLATO trial and showed that the use of ticagrelor was associated with a lower
thrombotic risk in ACS patients compared to the use of clopidogrel.
When comparing the patients in the PLATO trial (mostly younger and healthier
individuals) to a real-world population, there was a knowledge gap about the effect of ticagrelor
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on reducing the recurrent thrombotic events in the ACS population with AMI. Therefore, a
retrospective study was conducted by obtaining data of AMI patients treated with either
clopidogrel or ticagrelor from Swedish Heart Intensive Care Admission Registry to compare the
treatment between clopidogrel and ticagrelor on reducing the risk of ischemic stroke in a more
representative ACS population who most likely had prior MI. 3 This study included patients who
were treated at discharge with either clopidogrel or ticagrelor. Participants in this study were
divided into two cohorts. There were 23,447 participants in the early cohort which were treated
with 100% clopidogrel. The later cohort had 24,227 participants and were treated with either
clopidogrel (47.9%) or ticagrelor (52.1%).3 After a year of treatment, the later cohort showed an
increased platelet inhibition compared to the early cohort due to the higher frequency of
ticagrelor treatment in the later cohort. Incidence of ischemic stroke after one year was 2.8% vs.
2.4% for the early and later cohorts, respectively (p = 0.001).3 There was no significant
difference between the early and later cohorts in the most serious bleeding complication, such as
intracranial bleeding. Similar results were found in a pre-post case-control study using data from
the Cardio-STEMI Sanremo registry in Sanremo Hospital. The study included patients >18 years
old with a diagnosis of STEMI and excluded patients with type 4a or 5 AMI, who were
unavailable for follow-up visits or had severe comorbidity with very short life expectancy.5 In
this study, 401 eligible patients were enrolled between February 2011 and June 2013, in which
142 patients received ticagrelor and 259 received clopidogrel. This study showed the use of
ticagrelor resulted in a significant reduction of cardiovascular mortality at 1-year compared to
clopidogrel (5.4% reduction with ticagrelor vs 0.7% reduction with clopidogrel).5 This study also
showed a similar rate of BARC bleeding (Bleeding Academic Research Consortium criteria)
between the two groups.5 The results from these two studies were concordant with the results
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from the PLATO trial which showed the beneficial effect of ticagrelor on reducing the risk of
recurrent thrombosis and mortality rate in this high-risk subgroup.5 Therefore, these findings
suggested that ticagrelor may be a valid treatment option in this ACS population with MI. 1,3
At this point, ticagrelor has shown its effectiveness in reducing the risk of cardiovascular
adverse events in ACS patients with or without AMI. Additionally, the superior efficacy of
ticagrelor were also seen in high-risk ACS patients, such as in ACS patients with prior heart
attack; and this was proven in the Prevention of Cardiovascular Events in Patients with Prior
Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis
In Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. This trial randomized 21,162 patients
with prior MI (1–3 years) and additional high-risk features (≥65 years, prior MI, known
multivessel CAD, diabetes mellitus, or chronic kidney disease) to the ticagrelor 60 mg or 90 mg
group vs placebo twice daily in addition to aspirin. Patients with a history of coronary artery
bypass graft (CABG) surgery within the last 5 years as well as patients with increased risk of
bleeding were excluded. Patients were followed for a median of 33 months to evaluate the risk of
adverse cardiac events and major bleeding as defined by the Thrombolysis in Myocardial
Infarction (TIMI).8,9 As a result, 213 patients in the placebo group experienced stroke vs 91
patients in the ticagrelor group experienced stroke at the 30-day follow-up. This trial showed
significant reduction of the risk of stroke with ticagrelor (P=0.034).9 However, the use of
ticagrelor increased TIMI major bleeding (P<0.001) but with no statistically significant increase
in intracranial hemorrhage or fatal bleeding.9 From the PEGASUS-TIMI 54 trial, a group of
researchers also performed a pre-specified study to investigate the pattern of ischemic risk over
time and whether the efficacy and safety of ticagrelor were similar in early and late
randomization.10 The selection criteria and study method were described as above. In their study,
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they identified 28% of participants who had ≥5 years from MI at trial conclusion. When
examining patients according to the time from MI at randomization with either <2 years or ≥2
years, ticagrelor 60 mg showed greater benefit for the primary endpoint which was a composite
of adverse cardiovascular events in patients <2 years from MI compared to those ≥2 years from
MI.10 Treatment with the 90-mg dose yielded similar adverse cardiovascular outcomes in these
groups. This study also showed an increase in the rates of TIMI major bleeding with ticagrelor
60 mg at each year landmark, with the greatest increase in the first year (year 1 HR=3.22; year 2
HR=2.07; year 3 HR=1.65).10 With ticagrelor 90, the rates of TIMI bleeding were generally
higher than with ticagrelor 60 mg.10 In general, patients with prior MI >1 year from their ACS
event remain at long-term risk of recurrent atherothrombotic events. Ticagrelor consistently
reduced the risk of recurrent atherothrombotic in patients with prior MI regardless of early or late
administration of ticagrelor after an MI. The bleeding risk was also tolerable with a trend toward
lesser bleeding over time. Therefore, the prolonged therapy with Ticagrelor is supported in
patients who continue to tolerate the drug.10
Clearly, the PLATO trial as well as other blinded randomized controlled trials
demonstrated that dual antiplatelet treatment (DAPT) with ticagrelor reduced the rate of death
from vascular causes, stroke, or MI better than DAPT with clopidogrel. However, the
PLATO-trial included overall younger and healthier individuals who were at lower risk for
ischemic stroke than patients we typically would see in a real-life setting. Of the 18,624 eligible
patients in the PLATO trial, 1152 (6.2%) were high-risk patients who had a history of stroke or
TIA. This subgroup has a higher rate of morbidity and mortality; and we most likely encounter
them in a real clinical setting. Therefore, a group of researchers aimed to determine whether the
introduction of ticagrelor was associated with a lower rate of recurrent thrombotic events in ACS
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patients who previously had an ischemic stroke or TIA specifically in the PLATO trial. 1,11 Their
study, specifically to this subgroup, showed the reduction of a composite of death from vascular
causes, stroke, or MI and total mortality at 1 year with ticagrelor versus clopidogrel, which was
consistent with the overall trial results: 19.0% versus 20.8% and 7.9% versus 13.0%,
respectively.11 The major bleeding rate was not significantly different between patients assigned
to clopidogrel and ticagrelor with an adjusted hazardous rate (HR) of 1.10 vs HR of 1.11,
respectively. There was also no difference between clopidogrel and ticagrelor groups in
intracranial bleeding seen in this study.11
Since the PLATO trial excluded patients who received fibrinolytic therapy within 24
hours of ACS, consequently, there was a lack of evidence on the longer-term effects of ticagrelor
in ACS patients with STEMI treated with fibrinolytic therapy. Therefore, TicagRElor in pAtients
with ST-elevation myocardial infarction treated with pharmacological Thrombolysis (TREAT)
trial was conducted to evaluate the efficacy and safety data of ticagrelor when compared with
clopidogrel in this subgroup that was excluded from the PLATO trial.12 The TREAT trial was a
multicenter, international, blinded, and randomized controlled study involving 10 countries. This
trial enrolled 3,799 patients (age less than 75 years) with STEMI receiving fibrinolytic therapy
from November 2015 to November 2017. The trial excluded individuals who were
contraindicated against the study drugs, on other oral anticoagulation therapy, and who were at
an increased risk of bradycardia. Eligible patients were randomly assigned, in a 1:1 ratio, to
ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) or clopidogrel (300- to 600-mg
loading dose, 75 mg daily thereafter). The rates of cardiovascular mortality, MI, stroke, or other
arterial thrombotic events were evaluated at two periods: 30 days and 12 months.12,13 As a result,
the trial showed better reduction in the rates of cardiovascular mortality in the ticagrelor group at
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both timelines. Mortality outcomes occurred in 4.0% (in 30 days) and 6.7% (in 12 months) of
patients receiving ticagrelor vs 4.3% (in 30 days) and 7.3% (in 12 months) of patients receiving
clopidogrel.13 Again, there were no significant differences between ticagrelor and clopidogrel
groups in major, fatal, and intracranial bleeding.13 Overall, these findings would provide useful
data to assist physicians in clinical decision and suggested that ticagrelor may represent a
potential alternative antiplatelet agent that can be used after fibrinolytic therapy.12,13
Elderly patients represent a significant proportion of those with ACS. Unfortunately, this
ACS subgroup is at higher risk of recurrent thrombotic events and major bleeding. Indeed, an
80-year-old ACS patient has three-fold higher risk of recurrent ischemic stroke compared to a
60-year-old ACS patient. 2 Since the PLATO trial were mostly younger and healthier individuals,
a group of researchers conducted a meta-analysis to evaluate the efficacy of ticagrelor in this
compromised subgroup. This included six qualified randomized controlled trials (RCT) with
complete data published between 2009-2020 comparing the efficacy between the two groups,
ticagrelor vs clopidogrel, on a background of aspirin at the 12-month follow-up.2 Overall, this
study included 21,827 patients who were greater than or equal to 60 years old with coronary
heart disease, such as stable angina, unstable angina, STEMI or non-STEMI. This review found a
significant decrease in the incidence of adverse cardiovascular events in the ticagrelor group vs
clopidogrel group (9.23% vs 10.57%, respectively). However, the use of ticagrelor also increased
the incidence of minor or major bleeding compared with the use of clopidogrel in the elderly
population (11.51% vs 10.34 %, respectively).2
The use of ticagrelor has shown the beneficial effect on reducing the risk of subsequent
thrombotic events in general ACS patients and even in high-risk individuals who either had prior
MI or stroke. However, its effect on ACS patients with comorbidities such as diabetes mellitus
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(DM) was unclear. Therefore, a double-blinded, randomized controlled trial was performed to
examine whether adding ticagrelor to aspirin improves the outcomes in patients with stable
coronary artery disease (CAD) and DM.14 A total of 19,220 patients were enrolled in this trial.
Eligible patients are at least 50 years with stable CAD and type 2 DM. Patients with previous MI
or stroke or patients who were receiving dual antiplatelet therapy were excluded. Enrolled
patients were assigned to receive either ticagrelor (90 mg twice daily) plus aspirin (75 to 150 mg)
or placebo plus aspirin (75 to 150 mg) in a 1:1 ratio. After the results from the PEGASUS–TIMI
54 trial were published, the protocol of this trial was amended; and the dose of ticagrelor was
reduced to 60 mg twice daily instead of 90 mg twice daily in May 2015.14 The primary efficacy
outcome was a composite of cardiovascular death, MI, or stroke. The primary safety outcome
was major bleeding as defined by the Thrombolysis in Myocardial Infarction (TIMI).14 At the
median follow-up of 39.9 months, this trial showed a lower incidence of ischemic cardiovascular
events in the ticagrelor group than in the placebo group, which was 7.7% vs. 8.5%,
respectively.14 The incidence of major bleeding was higher in the ticagrelor group compared to
the clopidogrel group (0.2% vs. 0.1%, respectively).14 Since the risk of a composite outcome was
not significantly lower in the ticagrelor group than in the placebo group while the risk of major
bleeding tended to be higher in the Ticagrelor group, the findings suggested that ticagrelor
therapy did not have a favorable risk–benefit ratio in this trial population.14 Addition to these
findings, a trial from Korea was conducted between November 2011 and December 2015 to
compare 1-year clinical outcomes between ticagrelor and clopidogrel in this ACS with DM
subgroup.15 This trial obtained data from Acute Myocardial Infarction Registry which enrolled
3985 patients with MI and diabetes who underwent PCI to ticagrelor (90 mg twice daily) and
clopidogrel (75 mg once daily). This trial excluded patients with age ≥75, body weight <60 kg,
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history of transient ischemic attack (TIA) or stroke, or contraindication to ticagrelor.15 Same as
the previous described trial, this study showed no significant difference in the composite of
cardiac death, recurrent MI, or stroke (p = .084), but an increase in the major bleeding risk in the
ticagrelor group (p = .042) at 1-year follow-up.15
Despite the superior efficacy of DAPT with ticagrelor over clopidogrel, the increased risk
of bleeding was a concern when using ticagrelor in patients after ACS. Therefore, a group of
researchers performed a study using data from the Register of Information and Knowledge
About Swedish Heart Intensive Care Admissions to examine any association between ticagrelor
and intracranial hemorrhage (ICH) in AMI patients. 16 The population in their study were 47,674
ACS patients with AMI which were divided into two cohorts. The first cohort had 23,447
patients and treated with 100% clopidogrel, while the later cohort had 24,227 patients and treated
with either clopidogrel (47.8%) or ticagrelor (52.1%).16 This study showed no significant
difference in the incidence of ICH between the two cohorts with 0.59% of patients with ICH
found in the first cohort and 0.52% found in the second cohort.16 Even though this study showed
no increased risk of the fatal bleed-ICH associated with the use of ticagrelor, many previous
studies showed that DAPT of ticagrelor and aspirin could cause an increase in minor and major
bleeding events. Therefore, several groups of researchers had conducted studies to develop
strategies to reduce this known adverse effect of ticagrelor.
The Ticagrelor With Aspirin or Alone in High Risk Patients After Coronary Intervention
(TWILIGHT) trial was conducted to determine whether ticagrelor monotherapy would cause less
clinically relevant bleeding while still maintaining the benefit in reducing thrombotic events in
ACS patients undergoing PCI with drug-eluting stents (DES).17 TWILIGHT was a randomized
controlled trial conducted in 187 sites across 11 countries at Mount Sinai. This study had 9006

16
Vu
participants with high-risk features undergoing PCI with DES. These patients were on dual
antiplatelet therapy (DAPT) with ticagrelor plus aspirin for 3 months. Then, 7119 patients who
were adherent and had no cardiovascular events were randomized to ticagrelor plus aspirin and
ticagrelor plus placebo for 12 months.17 Inclusion criteria were ACS patients aged ≥65 years with
additional comorbidities (prior MI, diabetes mellitus or chronic kidney disease). Patients who
had contraindication to aspirin or ticagrelor, had need for oral anticoagulation, or had prior
cardiogenic shock were excluded. The main outcome in this study were the Bleeding Academic
Research Consortium (BARC) bleeding rate and the composite of stroke, MI, or all-cause
death.17 Among this patient population, 7.6% of patients with ticagrelor plus aspirin and 3.6% of
patients with ticagrelor plus placebo experienced BARC bleeding (P < 0.001). In the meantime,
4.4% of patients with ticagrelor plus aspirin and 4.3% patients with ticagrelor plus placebo were
reported of having stroke, MI or death (P = 0.84).17 This study showed that ticagrelor
monotherapy reduced clinically bleeding events without increasing ischemic risk compared to
ticagrelor plus aspirin in ACS patients undergoing PCI with DES who have completed an initial
3-month course of DAPT.17 A study with a similar design was conducted in Korea found the
same results. It was a multicenter, randomized trial conducted in 3056 patients with ACS treated
with drug-eluting stents between August 2015 and October 2018. 18 In this study, after the prior 3
months of DAPT, eligible patients were randomly assigned in a 1:1 ratio to receive ticagrelor
monotherapy (n = 1527) vs ticagrelor-based 12-month DAPT (n = 1529). Similarly, researchers
found a decrease in the rate of major bleeding in the ticagrelor monotherapy group vs the
ticagrelor-based DAPT group (1.7% vs 3.0%, respectively).18 In the meantime, there was also a
reduction of adverse clinical events in patients with ticagrelor monotherapy at 1-year follow-up,
in which cardiovascular events occurred in 3.9% of patients with ticagrelor alone vs in 5.9% of
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patients with ticagrelor plus aspirin.18 Therefore, the findings from these two trials suggested that
ticagrelor monotherapy could be a promising strategy to reduce the bleeding risk while still
maintaining a maximal platelet inhibition activity after a short-term DAPT in ACS patients with
PCI.18
Another strategy to reduce the risk of major or fatal bleeding that several groups of
researchers had conducted studies on was to use a reduced dose of ticagrelor (60 mg) instead of
the standard dose (90 mg). Therefore, a single-center, randomized controlled trial in Bydgoszcz
was performed to compare the efficacy (antiplatelet effect) of the two ticagrelor maintenance
dose regimens (60 mg bid vs. 90 mg bid) in stable patients 1 month after AMI treated with PCI,
following an initial DAPT with ticagrelor 90 mg bid during the first 30 days after the ACS
onset.19 This study included ACS patients with STEMI or non-STEMI and excluded patients who
had chronic inflammatory disease, indications for chronic anticoagulation, or contraindication to
ticagrelor. There were 52 enrolled patients equally randomized to receive either reduced (60 mg
bid) or standard (90 mg bid) dose of ticagrelor after they received 90 mg ticagrelor bid and
aspirin 75 mg once daily for the first 30 days after AMI happened. 19 After 15 days of
randomization (45 days after AMI), the primary endpoint which was platelet reactivity index
(PRI) was assessed with the VASP (a platelet function testing assay). As a result, the reduced
dose (60 mg) vs. standard dose (90 mg) of ticagrelor showed no significant difference in platelet
inhibition activity [VASP: 10.4 vs. 14.1].19 Additionally, the same result was found in an
experimental study conducted in 1000 participants, in which ticagrelor 60 and 90 mg twice daily
both achieved near maximal platelet inhibition in patients with stable CAD with or without
history of MI.20 Therefore, these findings suggested the favorable effect of the reduced dose (60
mg) over the standard dose (90 mg) with less bleeding risk in treating ACS patients. 19
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Discussion/Analysis
Overall, dual antiplatelet therapy (DAPT) with ticagrelor compared with clopidogrel was
associated with the lower rate of death from vascular causes, MI, or stroke without an increase in
the rate of major bleeding in ACS patients in many trials and studies. The PLATO trial was one
of the biggest trials that successfully showed the superior efficacy of DAPT with ticagrelor over
DAPT with clopidogrel. One of the strengths of the PLATO trial was that it was a multicenter,
double-blinded, randomized controlled trial conducted from approximately 800 sites in 43
countries. The trial also had a big study size with 18,624 participants.4,6 Therefore, the results
from this study were reliable and had high generalizability to the intended population. Moreover,
these findings from the PLATO trial were also supported by the Platelet Reactivity in Acute
Stroke or Transient Ischemic Attack (PRINCE) trial, which was a prospective study conducted at
26 centers in China from 2015-2017. In the PRINCE trial, treatment with ticagrelor again
showed significant reduction in recurrent thrombotic events at the 90th day of treatment, which
were consistent with the PLATO results.7 The PRINCE trial had some limitations such as 15% of
patients were lost to follow-up for evaluation. However, researchers observed similar results
after assuming all the missing data in both ways, high platelet activity vs not.7 With the
advantage of a randomized controlled trial that had an adequate study size of 675 participants,
the findings from the PRINCE trial were still considered reliable and useful data to support
bigger trials.
ACS patients with prior heart attack comprise a large number of the ACS population.
This subgroup is considered high-risk patients since they have a higher chance of recurrent
atherothrombotic events after experiencing ACS. The superior efficacy of ticagrelor was again
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proven for this high-risk population in many studies. In a retrospective study with data of AMI
patients treated with either clopidogrel or ticagrelor obtained from the Swedish Heart Intensive
Care Admissions Registry, the use of DAPT with ticagrelor showed reduction of ischemic stroke
in this ACS population who had prior MI. To avoid selection bias, this study compared the
efficacy between ticagrelor vs clopidogrel in two different cohorts. This was a big-scale study
with 23,447 participants in the first cohort and 24,227 participants in the second cohort.1,3
However, since it was a retrospective study, the results from this study demonstrated the need for
a randomized trial to further support the efficacy of ticagrelor in ACS patients with prior MI. The
Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin–Thrombolysis In Myocardial Infarction 54
(PEGASUS-TIMI 54) trial was one of the biggest randomized controlled trials that supported
these findings. In this trial, ticagrelor consistently reduced the risk of recurrent atherothrombotic
in patients with prior MI regardless of early or late administration after MI. The bleeding risk
was also tolerable with a trend toward lesser bleeding over time.8.9 Because of this, the prolonged
therapy with ticagrelor was supported in patients who continue to tolerate the drug.8.9 Since this
was a randomized controlled trial with a very big study size (21,162 patients), the results from
this study had high generalizability to the intended population and were useful to physicians in
selecting dual antiplatelet therapy in ACS patients with prior MI.
The PLATO was a big trial, however, it excluded patients who received fibrinolytic
therapy within 24 hours of ACS onset. Therefore, TREAT (TicagRElor in pAtients with
ST-elevation myocardial infarction treated with pharmacological Thrombolysis) trial was
conducted to evaluate the efficacy and safety data of ticagrelor when compared with clopidogrel
in STEMI patients treated with fibrinolytic therapy. In this study, the use of ticagrelor was again
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superior compared to the use of clopidogrel in reducing the rate of cardiovascular mortality, MI,
stroke, or other arterial thrombotic events at 3-months and 12-month follow-ups. Moreover, there
was no significant difference between ticagrelor and clopidogrel groups in major, fatal, and
intracranial bleeding.12,13 Since TREAT was a multicenter, international, blinded, and randomized
controlled study involving 10 countries with 3,799 participants, the results from this study had
high generalizability and would provide useful data to assist physicians in choosing an effective
alternative antiplatelet agent that can be used after fibrinolytic therapy.
The use of ticagrelor has shown the beneficial effect on reducing the risk of subsequent
thrombotic events in many ACS high-risk subgroups, such as ACS with prior MI (STEMI or
non-STEMI), prior stroke, or with fibrinolytic therapy. However, in an ACS subgroup with
diagnosis of diabetes mellitus, two randomized controlled studies that were reviewed in this
paper showed no significant difference in the composite of cardiac death, recurrent MI or stroke
(p = .084), but an increase in the major bleeding risk in the ticagrelor group.14,15 Since the risk of a
composite outcome was not significantly lower in the ticagrelor group than in the placebo group
while the risk of major bleeding tended to be higher in ticagrelor group, the findings suggested
that ticagrelor therapy did not have a favorable risk–benefit ratio in this ACS subgroup..
Nonetheless, ticagrelor has shown its superior efficacy in reducing the risk of recurrent
atherothrombotic events over clopidogrel in the overall ACS population and even in high-risk
subgroups, such as elderly patients, or patients with prior MI or stroke. Since my literature
review was conducted from mostly prospective, blinded, and randomized controlled trials with
adequate study sizes, the findings from these studies were reliable and could be used to answer
my PICO question which was whether the use of DAPT with ticagrelor would prevent recurrent
thrombotic events better than DAPT with clopidogrel. Through these studies, my PICO question
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was answered. Treatment with ticagrelor as compared to clopidogrel significantly reduced the
rate of recurrent cardiovascular adverse events such MI or stroke. The safety data of ticagrelor
was also evaluated in these studies/trials. Even though most of the studies showed no significant
increase in the rate of overall major bleeding in patients with ACS, bleeding was still a known
adverse outcome of ticagrelor administration. Many studies have been conducted to figure out
strategies to reduce the risk of bleeding while still maintaining the maximal platelet inhibition
activity of ticagrelor. Indeed, researchers have tried to compare ticagrelor monotherapy with
DAPT. They also tried to compare the efficacy and safety of the reduced dose (60 mg) with the
standard dose (90 mg) of ticagrelor. Interestingly, the reduction of bleeding events was observed
in these studies while a maximal platelet inhibition activity was still maintained. Therefore, the
findings from these studies suggested ticagrelor monotherapy or reduced dose of Ticagrelor (60
mg) could be a promising strategy for clinicians in adjusting the bleeding risk when it was a
concern.17,18

Conclusion
Cardiovascular disease is a great concern and a leading cause of death worldwide. After
experiencing acute coronary syndrome, patients are at risk for further cardiovascular adverse
events such as MI or stroke. Patients with prior stroke or MI comprises high-risk ACS subgroups
since they are even at higher risk of having subsequent atherothrombotic events. Patients with
prior ischemic stroke are often treated conservatively with either medications or interventions
such as percutaneous coronary intervention (PCI). Indeed, dual antiplatelet therapy (DAPT) is an
effective secondary prevention and an essential component of treatment after the patient
suffering from ACS. Until 2011, the standard DAPT in Sweden was still the combination of
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clopidogrel and aspirin.1,2 However, clinicians rapidly switched to ticagrelor, a P2Y12-inhibitor,
as the preferred treatment option after it was introduced in 2011.1 It is because clopidogrel is a
prodrug which needs liver metabolism to be activated. Therefore, the onset of clopidogrel is
slow, and many unexpected variations in drug activity are observed.4 Compared to clopidogrel,
ticagrelor is not a prodrug and does not require metabolic activation. Moreover, its effect on
platelet inhibition is more pronounced; and recovery of platelet function with ticagrelor is faster
than clopidogrel.5 With these advantageous features, ticagrelor was a promising alternative dual
antiplatelet therapy that was worth studying. Indeed, through the literature review from many big
blinded, randomized controlled trials and studies, ticagrelor has successfully shown its superior
efficacy in reducing the rate of cardiovascular adverse events in ACS patients compared to
clopidogrel. Even though the risk of bleeding was a main concern of ticagrelor, many studies
showed no significant differences in the rate of major bleeding between ticagrelor and
clopidogrel. In conclusion, compared to DAPT with clopidogrel, DAPT with ticagrelor is an
effective alternative secondary prevention which better reduces recurrent thrombotic events in
patients currently experiencing ACS. Hopefully, the findings from this comprehensive review
would help clinicians in selecting DAPT for ACS patients and therefore further prevent deaths
and disabilities in these patients.
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Dual Antiplatelet Therapy with Ticagrelor vs Clopidogrel
in Patients with Acute Coronary Syndrome
Binh Vu, PA-S; Kurt DeVine, MD
Augsburg University PA Program
BACKGROUND
Dual antiplatelet therapy
(DAPT) is an essential
component of treatment after
patients suffering from acute
coronary syndrome (ACS).
Compared to clopidogrel,
ticagrelor is not a prodrug and
does not require metabolic
activation to inhibit the platelet
P2Y12 receptor. Therefore, its
effect on platelet inhibition is
more pronounced compared to
clopidogrel.

PURPOSE
•To evaluate the efficacy and
safety data of ticagrelor when
compared with clopidogrel in
patients with ACS.
•To help clinicians in selecting
DAPT for ACS patients and
therefore further prevent
deaths and disabilities in these
patients.

METHODOLOGY
The review was conducted using Tripdatabases and Pubmed search engines with terms: “dual antiplatelet
therapy,” “antiplatelet monotherapy,” “ticagrelor vs clopidogrel,” “cardiovascular adverse events,”
“coronary heart disease,” “acute coronary syndrome,” “myocardial infarction.” Inclusion criteria were
retrospective or prospective randomized controlled studies with complete data that recently published.
Exclusion criteria were case reports, repeated publications, animal experiments, and studies with
incomplete data. 20 studies were selected in this review with 16 studies published within the last five years.
Participants were ACS patients who were at least 18 years old with or without ST-elevation in addition to
one or more cardiovascular risk factors. In most of the selected studies, the main outcomes were the rate
of cardiovascular mortality, MI, stroke, or other atherothrombotic events and the major bleeding risk.
“IRB application has been submitted to Augsburg University Institutional Review Board.”

ANALYSIS & LIMITATIONS
•As a multicenter, double-blinded, and randomized controlled trial with big sample size of 18,624 ACS
participants, PLATO trial successfully showed the superior efficacy of DAPT with ticagrelor over DAPT with
clopidogrel in reduction of recurrent thrombotic event after ACS, in which a composite of death from
vascular causes, stroke, or MI at 12 months had occurred in 9.8% of patients receiving ticagrelor vs 11.7% of
those receiving clopidogrel (P<0.001).1
•ACS patients with prior ischemic stroke or TIA have higher risk of recurrent thrombotic events.
Introduction of ticagrelor was also associated with a lower rate of total mortality at 1 year with ticagrelor
versus clopidogrel, 7.9% versus 13.0% respectively.2
•PEGASUS-TIMI 54 was a randomized trial with 21,162 ACS participants with prior MI again showing the
superior efficacy of ticagrelor over placebo, in which 213 patients in the placebo group vs 91 patients in the
ticagrelor group experienced stroke at the 30-day follow-up.3
•DAPT with ticagrelor was associated with the major bleeding risk in some trials. However, using a reduced
dose of ticagrelor (60 mg) or ticagrelor monotherapy had showed a lower risk of this complication. 4
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DISCUSSION
Compared to DAPT with clopidogrel, DAPT with
ticagrelor is an effective alternative secondary
prevention which better reduces recurrent
thrombotic events in patients currently
experiencing ACS. The findings from this review
would be useful sources for clinicians in
selecting DAPT for ACS patients and therefore
further prevent deaths and disabilities in these
patients.
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